Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 15, 2005, Pages 3496-3500

  Miller, John F ^a   Brieger, Michael ^a,b   Furfine, Eric S ^a,c   Hazen, Richard J ^a   Kaldor, Istvan ^a   Reynolds, David ^a,d   Sherrill, Ronald G ^a   Spaltenstein, Andrew ^a  

^a GLAXOSMITHKLINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d King Pharmaceuticals   (United States)

Author keywords

Antiretroviral; Antiviral; Arylsulfonamide; Drug resistance; HIV protease; Hypersusceptibility

Indexed keywords

ATAZANAVIR; CARBAMIC ACID METHYL ESTER; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; VIRUS MUTANT; WILD TYPE;

ANIMALS; ANTI-HIV AGENTS; DOGS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV; HIV PROTEASE INHIBITORS; INHIBITORY CONCENTRATION 50; MUTATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 21744449446     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.05.129     Document Type: Article

References (16)

1. F.J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, D.J. Aschman, and S.D. Holmberg N. Engl. J. Med. 338 1998 853
2. S.M. Hammer, K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, J.S. Currier, J.J. Eron, J.E. Feinberg, H.H. Balfour, L.R. Deyton, J.A. Chodakewitz, M.A. Fischl, J.P. Phair, L. Pedneault, B.Y. Nguyen, and J.C. Cook N. Engl. J. Med. 337 1997 725
3. D. Boden, and M. Markowitz Antimicrob. Agents Chemother. 42 1998 2775
4. M. Tisdale, R.E. Myers, B. Maschera, N.R. Parry, N.M. Oliver, and E.D. Blair Antimicrob. Agents Chemother. 39 1995 1704
5. J.F. Miller, E.S. Furfine, M.H. Hanlon, R.J. Hazen, J.A. Ray, L. Robinson, V. Samano, and A. Spaltenstein Bioorg. Med. Chem. Lett. 14 2004 959
6. P. Chen, P.T.W. Cheng, S.H. Spergel, R. Zahler, X. Wang, J. Thottathil, J.C. Barrish, and R.P. Polniaszek Tetrahedron Lett. 18 1997 3175
7. Tao, E.V.P.; Miller, W.D. U.S. Patent 5,387,681, 1995.
8. A.K. Ghosh, J.F. Kincaid, D.E. Walters, Y. Chen, N.C. Chaudhuri, W.J. Thompson, C. Culberson, P.M.D. Fitzgerald, H.Y. Lee, S.P. McKee, P.M. Munson, T.T. Duong, P.L. Darke, J.A. Zugay, W.A. Schleif, M.G. Axel, J. Lin, and J.R. Huff J. Med. Chem. 39 1996 3278
9. The wild-type virus HXB2 was derived from the pHXB2-D molecular clone For further details see: A.G. Fischer, E. Collati, L. Ratner, R.C. Gallo, and F. Wong-Stall Nature (London) 316 1985 262
10. The EP13 and D545701 strains are engineered viruses containing mutations associated with clinically observed PI therapy failure in patients exposed to multiple protease inhibitors. They contain the following mutations relative to the consensus sequence of wild-type virus. EP13: protease-M46I, L63P, A71V, V82F/L, I84V; no reverse transcriptase mutations. D545701: protease-L10I, L19Q, K20R, E35D, M36I, S37N, M46I, I50V, I54V, I62V, L63P, A71V, V82A, L90M; reverse transcriptase-E28K, K32E, V35I, T39S/T, E40D/V/Y/F, M41M/L, K43E, Y181Y/C.
11. S.M. Daluge, D.J.M. Purifoy, P.M. Savina, M.H. St Clair, N.R. Parry, I.K. Dev, P. Novak, K.M. Ayers, and J.E. Reardon Antimicrob. Agents Chemother. 38 1994 1590
12. is below the lower limit (approximately 10 pM) measurable using standard steady-state kinetics techniques. As a result, enzyme inhibition data was no longer useful in driving our SAR program and we were forced to rely exclusively on cellular antiviral data.
13. A.J. Leigh Brown, S.D.W. Frost, B. Good, E.S. Daar, V. Simon, M. Markowitz, A.C. Collier, E. Connick, B. Conway, J.B. Margolick, J.P. Routy, J. Corbeil, N.S. Hellmann, D.D. Richman, and S.J. Little J. Virol. 78 2004 2242
14. W. Resch, R. Ziermann, N. Parkin, A. Gamarnik, and R. Swanstrom J. Virol. 76 2002 8659
15. G.N. Kumar, V.K. Jayanti, M.K. Johnson, J. Uchic, S. Thomas, R.D. Lee, B.A. Grabowski, H.L. Sham, D.J. Kempf, J.F. Denissen, K.C. Marsh, E. Sun, and S.A. Roberts Pharm. Res. 21 2004 1622
16. M. Hurst, and D. Faulds Drugs 60 2000 1371